HC Wainwright & Co. Maintains Buy on Clearside Biomedical, Lowers Price Target to $5
HC Wainwright & Co. analyst Yi Chen maintains Clearside Biomedical (NASDAQ:CLSD) with a Buy and lowers the price target from $10 to $5.
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Recap Of Tuesday’s Biotech Catalysts – End of The Day Summary
European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg…
Clearside Biomedical Sees Initial-Stage Chronic Eye Disorder Study Results In Q4 2022
Clearside Biomedical (NASDAQ: CLSD) has completed dosing in Cohorts 3 and 4 of OASIS study of its lead drug CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
Clearside Biomedical: Q1 Earnings Insights
Clearside Biomedical (NASDAQ:CLSD) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell
• Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
Clearside Biomedical Says Poster Presentation At ARVO 2022 Annual Meeting Demonstrates Versatility Of Suprachoroidal Delivery Technology
Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology
- Multiple Poster Presentations on XIPERE® and Gene Therapy Delivery Utilizing
68 Biggest Movers From Yesterday
Gainers
Sonim Technologies, Inc. (NASDAQ: SONM) shares jumped 103.3% to settle at $1.22 on Tuesday after the company announced its XP8 smartphone has integrated with the Walkie Talkie in Microsoft Teams.